Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 797 across all filing types
Latest filing 2023-05-19 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2023-05-19 English
Pharming Group reports on results of the 2023 Annual General Meeting of Shareholders
AGM Information Classification · 99% confidence The document title explicitly states it concerns the 'uitkomsten jaarlijkse Algemene Vergadering van Aandeelhouders 2023' (outcomes of the Annual General Meeting 2023). The text details the approval or rejection of various proposals voted upon during the AGM, including the reappointment of board members and authorizations for share issuance. This content directly relates to the proceedings and results of the Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R). Although it mentions voting results, the primary context is the overall meeting outcome and related announcements, making AGM-R more specific than DVA (Declaration of Voting Results & Voting Rights Announcements), which usually focuses solely on the final tally.
2023-05-19 English
Pharming Group reports on results of the 2023 Annual General Meeting of Shareholders
AGM Information Classification · 99% confidence The document explicitly states it reports on the 'results of the 2023 Annual General Meeting of Shareholders (AGM)'. It details which proposals were approved (reappointment of directors, authorization for general financing) and which were not voted on or withdrawn (authorization for M&A financing). This content directly relates to the outcomes and proceedings of the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R).
2023-05-19 English
Pharming Group reports financial results for the first quarter of 2023
Earnings Release Classification · 99% confidence The document is titled "Pharming Group publiceert financiële resultaten over het eerste kwartaal van 2023" (Pharming Group publishes financial results for the first quarter of 2023) and explicitly states it is the "voorlopige, niet-gecontroleerde financiële verslag over het eerste kwartaal eindigend op 31 maart 2023" (preliminary, unaudited financial report for the first quarter ending March 31, 2023). It contains detailed financial tables comparing Q1 2023 results to Q1 2022, discusses revenue, profit/loss, and cash balance for the period. This content structure is characteristic of a comprehensive quarterly financial report, which aligns with the definition of an Interim / Quarterly Report (IR). It is not just an Earnings Release (ER) as it contains detailed financial statements, nor is it an Annual Report (10-K) as it covers only one quarter. Q1 2023
2023-05-11 English
Pharming Group reports financial results for the first quarter of 2023
Earnings Release Classification · 98% confidence The document explicitly states in the title and opening paragraph that it presents the "financial results for the first quarter of 2023" and is a "preliminary, unaudited financial report for the first quarter ended March 31, 2023." This content structure, focusing on quarterly performance, key financial tables (Income Statement, Balance Sheet), and management commentary on recent results, strongly indicates a quarterly financial report. The closest specific category for a comprehensive, period-specific financial report shorter than a year is 'Interim / Quarterly Report' (IR). While it contains elements of an Earnings Release (ER) (key highlights), the depth of the financial tables and management discussion suggests it is the full interim report, not just the initial press release highlights. It is not a 10-K (Annual Report) because the period is Q1, not the full year. It is not an RPA because it is the report itself, not just an announcement of its publication. Q1 2023
2023-05-11 English
6-K Filing
Regulatory Filings
2023-05-11 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.